| SEC For | | | | | с с г | | | | EVOUA | | | SCION | | | | | |
|--|---|--|---|---|---|---|------------|--|-------------------------|--|--|---|--|--|--|---|--|
| FORM 4 UNITED | | | | STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 | | | | | | | | | | OMB APPROVAL | | | |
| Section 16. Form 4 or Form 5 obligations may continue. See | | | | | | T OF CHANGES IN BENEFICIAL OWNERSHI | | | | | | | | OMB Number: 3235-0287 Estimated average burden hours per response: 0.5 | | | |
| 1. Name and Address of Reporting Person [*] McNeill Jonathan | | | | | 2. Issuer Name and Ticker or Trading Symbol Dyne Therapeutics, Inc. [DYN] | | | | | | | eck all applie Directo | cable) | , 10% Owne | | | |
| | (Last) (First) (Middle) C/O DYNE THERAPEUTICS, INC. 1560 TRAPELO ROAD | | | | 3. Date of Earliest Transaction (Month/Day/Year) 07/05/2022 | | | | | | | | X below) below) See Remarks | | | | |
| (Street) WALTHAM MA 02451 | | | | 4. | 4. If Amendment, Date of Original Filed (Month/Day/Year) | | | | | | | Individual or Joint/Group Filing (Check Applicable ine) X Form filed by One Reporting Person Form filed by More than One Reporting Person | | | | | |
| (City) | (S | , | (Zip) Die I - Non-Der | ivativ | ve Se | curities | s Ac | auired. D | isposed (| of. or Be | neficial | lv Owned | 1 | | | | |
| 1. Title of Security (Instr. 3) 2. Transa Date (Month/D | | | | | n : (ear) i | 2A. Deemo Execution if any (Month/Da | ed Date | a, 3. 4. Secu Transaction Dispos Code (Instr. 5) | | ities Acquire d Of (D) (Ins | ed (A) or | 5. Amou Securitie Beneficia | nt of s ally following | Form (D) or | Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | |
| | | | | | | | | Code | / Amount | (A) or (D) | ^r Price | Transact (Instr. 3 a | ion(s) | | ` | | |
| | | - | Table II - Deriv (e.g., | | | | | | sposed of , converti | | | Owned | | | | | |
| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transa Code 8) | | 5. Number n of | | 6. Date Exercisable and Expiration Date (Month/Day/Year) | | 7. Title an of Securit Underlyin Derivative (Instr. 3 an | ies g Security | 8. Price of Derivative Security (Instr. 5) | 9. Number derivative Securities Beneficial Owned Following Reported Transaction (Instr. 4) | s Ily I | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | Beneficial Ownership (Instr. 4) | |
| | | | | Code | v | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | | | | | | |
| Stock Option (right to buy) | \$5.54 | 07/05/2022 | | A | | 21,666 | | (1) | 07/30/2030 | Common Stock | 21,666 | \$0.00 | 21,66 | 6 | D | | |

Explanation of Responses:

1. The option was granted on July 31, 2020, with 100% of the option to vest upon the clearance date of an Investigational New Drug (IND) application submitted to the U.S. Food and Drug Administration (FDA) by the Company with respect to one of its product candidates. On July 5, 2022, in connection with the clearance by the FDA of the Company's IND application for DYNE-251, the Compensation Committee determined that the performance condition had been achieved.

Remarks:

Senior Vice President of Business Development

/s/ Richard Scalzo, Attorney-in-07/06/2022

Fact

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.